Libya's Ministry of Health is expanding its PharmaGate digital platform to centralise the registration and oversight of pharmaceutical companies, aiming to improve transparency, efficiency, and data management in the sector.
The Ministry of Health in Libya is moving forward with the development of its PharmaGate digital system, designed to modernise the regulation and registration of pharmaceutical companies operating in the country. The initiative aims to streamline administrative processes, reduce in-person visits, and create a unified database for both local and foreign firms.
PharmaGate functions as an electronic portal, enabling companies to register and submit required documentation remotely. This approach limits the need for physical attendance at the Ministry's headquarters to only the final procedural steps, such as completing outstanding requirements and collecting official licenses. According to the Ministry, this digital transformation is intended to save time and effort for both regulators and companies, while also supporting more efficient review and follow-up procedures.
Centralised data and increased transparency
The system is structured to automate registration procedures and organise technical and legal files, contributing to a more transparent and accountable regulatory environment. By establishing a centralised and unified database, PharmaGate is expected to facilitate contracting, supply management, and the monitoring of pharmaceutical sector activities. The Ministry reports that 131 local pharmaceutical companies and 53 foreign companies have already been registered through the platform.
Next phase: product registration and digital expansion
As part of ongoing development, the Ministry is working to introduce an electronic registration service for pharmaceutical products. This planned expansion will further standardise data and simplify the registration and monitoring of medicines and related products. The Ministry positions this as a key step in Libya's broader digital transformation agenda for the health sector, with the goal of enhancing regulatory oversight and supporting the integrity of pharmaceutical supply chains.
